Novartis's misfortunes with Gilenya could provide a boost for other MS drug makers
This article was originally published in Scrip
Executive Summary
The misfortunes suffered by Novartis with its multiple sclerosis (MS) drug, Gilenya (fingolimod), could provide an unexpected advantage to rival players in this market. Teva and Biogen Idec have already seen their share price boosted, while some analysts believe Novartis needs to take swift action to minimise its losses.